Benjamin T. Ristau

Dr. Benjamin T. Ristau


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Urology
Verified
Journal Article
Closed access
BRBenjamin T Ristau
Benjamin T Ristau
JMJudi Manola
Judi Manola
NHNaomi B. Haas
Naomi B. Haas
DHDaniel Y.C. Heng
Daniel Y.C. Heng
EMEdward M. Messing
Edward M. Messing
RURobert G. Uzzo
Robert G. Uzzo
Lymphadenectomy is a well established practice for many urological malignancies but its role in renal cell carcinoma is less clear. Our primary objective was to determine whether lymphadenectomy impacted survival in patients with fully resected, high risk renal cell carcinoma. Patients with fully resected, high risk, nonmetastatic renal cell carcinoma were randomized to adjuvant sorafenib, sunitinib or placebo in the ASSURE (Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma) trial. Lymphadenectomy was performed for cN+ disease or at surgeon discretion. Patients treated with lymphadenectomy were compared to patients in the trial who did not undergo lymphadenectomy. The primary outcome was overall survival associated with lymphadenectomy. Secondary outcomes were disease free survival, factors associated with performing lymphadenectomy and surgical complications. Of the 1,943 patients in ASSURE 701 (36.1%) underwent lymphadenectomy, including all resectable patients with cN+ and 30.1% of those with cN0 disease. A median of 3 lymph nodes (IQR 1-8) were removed and the rate of pN+ disease in the lymphadenectomy group was 23.4%. There was no overall survival benefit for lymphadenectomy relative to no lymphadenectomy (HR 1.14, 95% CI 0.93-1.39, p = 0.20). In patients with pN+ disease who underwent lymphadenectomy no improvement in overall or disease-free survival was observed for adjuvant therapy relative to placebo. Lymphadenectomy did not confer an increased risk of surgical complications (14.2% vs 13.4%, p = 0.63). The benefit of lymphadenectomy in patients undergoing surgery for high risk renal cell carcinoma remains uncertain. Future strategies to answer this question should include a prospective trial in which patients with high risk renal cell carcinoma are randomized to specific lymphadenectomy templates.

1 December 2018 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
BRBenjamin T Ristau
Benjamin T Ristau
MAMatthew Allaway
Matthew Allaway
DCDemetri Cendo
Demetri Cendo
JHJohn Hart
John Hart
JRJason Riley
Jason Riley
PAPeter C. Albertsen
Peter C. Albertsen

12 September 2018 in Cancer
Verified
Journal Article
Closed access
PDF file
BRBenjamin T Ristau
Benjamin T Ristau
EHElizabeth A. Handorf
Elizabeth A. Handorf
DCDavid B. Cahn
David B. Cahn
AKAlexander Kutikov
Alexander Kutikov
RURobert G. Uzzo
Robert G. Uzzo
MSMarc C. Smaldone
Marc C. Smaldone

1 December 2016 in European Urology Focus
Verified
Journal Article
Closed access
BRBenjamin T Ristau
Benjamin T Ristau
AKAlexander Kutikov
Alexander Kutikov
RURobert G. Uzzo
Robert G. Uzzo
MSMarc C. Smaldone
Marc C. Smaldone

1 December 2015 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
BRBenjamin T Ristau
Benjamin T Ristau
ADA.G. Dudley
A.G. Dudley
DCD.P. Casella
D.P. Casella
MDM.E. Dwyer
M.E. Dwyer
JFJ.A. Fox
J.A. Fox
MOM.C. Ost
M.C. Ost

1 May 2017 in Urologic Clinics of North America
Verified
Journal Article
Closed access
BRBenjamin T Ristau
Benjamin T Ristau
ACAndres F. Correa
Andres F. Correa
RURobert G. Uzzo
Robert G. Uzzo
MSMarc C. Smaldone
Marc C. Smaldone